Palbociclib

Palbociclib
Clinical data
Trade names	Ibrance, others
Other names	PD-0332991
AHFS/Drugs.com	Monograph
MedlinePlus	a615013
License data	EU EMA: by INN; US DailyMed: Palbociclib;
Pregnancy; category	AU: D;
Routes of; administration	By mouth
ATC code	L01EF01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Bioavailability	46%
Protein binding	85%
Metabolism	Liver (CYP3A, SULT2A1, glucuronidation)
Elimination half-life	29 (±5) hours
Excretion	74% feces, 18% urine
Identifiers
	IUPAC name 6-Acetyl-8-cyclopentyl-5-methyl-2-{[5-(1-piperazinyl)-2-pyridinyl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one;
CAS Number	571190-30-2;
PubChem CID	5330286;
DrugBank	DB09073;
ChemSpider	4487437;
UNII	G9ZF61LE7G;
KEGG	D10372 ;
ChEBI	CHEBI:85993 ;
ChEMBL	ChEMBL189963;
PDB ligand	LQQ (PDBe, RCSB PDB);
CompTox Dashboard (EPA)	DTXSID40972590 ;
ECHA InfoCard	100.238.221
Chemical and physical data
Formula	C24H29N7O2
Molar mass	447.543 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2N(c1nc(ncc1/C(=C2/C(=O)C)C)Nc3ncc(cc3)N4CCNCC4)C5CCCC5;
	InChI InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29); Key:AHJRHEGDXFFMBM-UHFFFAOYSA-N;

Palbociclib, sold under the brand name Ibrance among others, is a medication developed by Pfizer for the treatment of HR-positive and HER2-negative breast cancer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.